Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endosense launches study of its TactiCath ablation catheter

This article was originally published in Clinica

Executive Summary

Swiss firm Endosense has enrolled the first of 300 patients in the TOCCASTAR clinical study, assessing the TactiCath contact force ablation catheter in the treatment of symptomatic paroxysmal atrial fibrillation (AF). The prospective, randomised, investigational device exemption (IDE) trial is designed to evaluate the effectiveness and safety of TactiCath compared with an approved catheter. Results will be used to support a premarket approval (PMA) application to the US FDA for the TactiCath catheter and accompanying TactiSys system. Geneva-based Endosense launched the catheter outside the US in April 2010; Biotronik is its exclusive distributor in Europe, Latin America, Canada, Africa and the Middle East.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT096484

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel